Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Guggenheim

Guggenheim Maintains Buy Rating for Meta Platforms: Here's What You Need To Know

Guggenheim has decided to maintain its Buy rating of Meta Platforms (NASDAQ:FB) and lower its price target from $275.00 to $250.00. Shares of Meta Platforms are trading down 2.94% over the last 24 hours, at $196.67 per share.

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

What To Know About Guggenheim's Downgrade of Spotify Technology

What To Know About Guggenheim's Downgrade of Spotify Technology

Guggenheim downgraded its rating of Spotify Technology (NYSE:SPOT) to Neutral with a price target of $95.00, changing its price target from $200.00 to $95.00. Shares of Spotify Technology are trading down 12.12% over the last 24 hours, at $97.03 per share.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Guggenheim Maintains Buy Rating for Albertsons Companies, Raises Price Target To $37

Guggenheim has decided to maintain its Buy rating of Albertsons Companies (NYSE:ACI) and raise its price target from $34.00 to $37.00. Shares of Albertsons Companies are trading up 4.41% over the last 24 hours, at $33.38 per share.

Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Why This Teladoc Health Analyst Expects 25%-30% Revenue Growth

Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022

Guggenheim Is Bullish On ESS Tech, Sees Significant Upside

Guggenheim Is Bullish On ESS Tech, Sees Significant Upside

ESS Tech Inc (NYSE:GWH) coverage has been initiated with a Buy rating and a price target of $10 (implying an upside of 82.5%) by Guggenheim analyst Joseph Osha. The analyst cites ESS as one of a large group of companies over the past two decades aiming to make flow batteries work commercially. Osha views ESS…

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022

Analysts Slice Down This Pizza Chain's Price Targets

Analysts Slice Down This Pizza Chain's Price Targets

Analysts lowered their price target on Domino's Pizza Inc (NYSE:DPZ) following the company's Q4 results. Citi analyst Sergio Matsumoto lowered the price target to $480 (18% upside) from $540 and kept a Neutral rating on the shares. The analyst cited forecast decreases and market conditions for the reduced price target. Barclays analyst Jeffrey Bernstein lowered…

45 Stocks Moving In Friday's Mid-Day Session

45 Stocks Moving In Friday's Mid-Day Session

Gainers KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2 billion. Guggenheim upgraded KAR Auction Services from Sell to Neutral.

Read How Analysts Reacted To IAA's Q4 Results

Read How Analysts Reacted To IAA's Q4 Results

Truist analyst Stephanie Moore lowered the price target on IAA Inc (NYSE:IAA) to $50 (an upside of 40.5%) from $75 and maintained a Buy rating on the shares. The analyst mentioned the company reported a Q4 EBITDA miss and offered "mixed" FY22 guidance on EBITDA margin, but the subsequent 22% stock price decline is "overdone." Moore…

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Stephanie Moore

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

276,895 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play